![]() |
市場調查報告書
商品編碼
2008728
微生物組定序服務市場報告:按技術、研究類型、實驗室類型、應用、最終用戶和地區分類(2026-2034 年)Microbiome Sequencing Services Market Report by Technology (Sequencing by Synthesis, Sequencing by Ligation, Pyrosequencing, Sanger Sequencing, and Others), Research Type, Laboratory Type, Application, End User, and Region 2026-2034 |
||||||
2025年,全球微生物組定序服務市場規模達30.48億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到121.284億美元,2026年至2034年的複合年成長率(CAGR)為16.09%。推動市場成長的主要因素包括:公眾感染疾病率的上升、人們對包括糞便微生物移植(FMT)在內的基於微生物組的治療方法的興趣日益濃厚,以及微生物定序在獸醫學領域的應用不斷擴大。
微生物組定序服務是對棲息於各種環境(包括人體)中的微生物群落進行分析。這些專門的程序旨在識別和分析生活在特定生態系統(例如人體腸道、土壤和水體)中的各種微生物。利用先進的去氧核糖核酸(DNA) 定序技術,可以破解這些微生物的遺傳物質,從而使研究人員和醫療保健專業人員能夠了解這些微生物群落的組成、多樣性和功能。
公眾感染疾病率的不斷上升推動了對微生物組測序服務的需求,以研究宿主與病原體之間的關係,從而導致全球範圍內此類服務需求的成長。此外,人們對基於微生物組的治療方法(包括糞便微生物移植 (FMT))的興趣日益濃厚,而這些療法需要精確的微生物組分析以確保療效和安全性,這也促進了市場成長。同時,微生物組定序在獸醫學領域的應用日益廣泛,用於了解動物健康、預防疾病和提高畜牧生產性能,也對市場產生了正面影響。此外,製藥業的擴張促使人們更多地利用微生物組數據開發新藥,特別是針對胃腸道疾病的藥物,這也有助於市場成長。最後,依賴數據驅動決策的精密農業實踐的日益普及也推動了市場成長。
個人化醫療和治療方法的增加
隨著個人化醫療的日益普及,對微生物組定序服務的需求也日益成長,以便為每位患者提供量身定做的治療方案和介入措施。推動這項需求成長的一個因素是,人們逐漸認知到每個人的微生物組都是獨一無二的,並且會顯著影響其對治療的反應。微生物組數據對於最佳化益生菌攝取方案、提供飲食指導或預測藥物療效至關重要。患者和醫療專業人員越來越希望獲得此類信息,以期獲得更好的治療效果、最大限度地減少副作用並改善整體健康狀況。因此,隨著個人化醫療成為現代醫學的核心概念,對微生物組定序服務的需求也不斷上升。
消費者意識和健康意識的提高
消費者對微生物組在健康和福祉中的作用的認知正在穩步提升。人們越來越積極主動地關注自身健康,並探索最佳化微生物組以改善健康狀況的方法。這一趨勢的推動力來自消費級微生物組檢測套組的普及,這些試劑盒能夠深入了解個體的腸道菌叢。隨著消費者對自身微生物組與各種健康因素之間關聯的理解不斷加深,他們擴大使用微生物組定序服務來獲取更詳細的分析和個人化建議。公眾興趣的激增,加上人們尋求更明智的生活方式選擇和飲食調整以促進更健康的微生物組,共同推動了對微生物組測序服務的需求。
加強監管要求和品質保證
醫療、農業和食品安全領域的監管機構日益認知到微生物組數據在確保安全和品質標準方面的重要性。例如,在食品行業,微生物組測序用於透過識別潛在病原體和腐敗菌來監測和改進食品安全。同樣,農業監管機構可能會強制要求進行微生物組評估,以確保永續的農業實踐。遵守這些法規需要使用微生物組定序服務來維持高品質的標準,因此,致力於滿足監管要求並確保產品安全的公司和組織對微生物組定序的需求持續存在。
The global microbiome sequencing services market size reached USD 3,048.0 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 12,128.4 Million by 2034, exhibiting a growth rate (CAGR) of 16.09% during 2026-2034. The increasing incidences of infectious diseases among the masses, rising inclination towards microbiome-based therapeutics, including FMT, and the growing adoption of microbiome sequencing in veterinary medicine are some of the major factors propelling the market.
Microbiome sequencing services involve the analysis of microbial communities that inhabit various environments, including the human body. They are specialized procedures designed to identify and analyze the diverse microorganisms living in a particular ecosystem, such as the human gut, soil, or water. They use advanced deoxyribonucleic acid (DNA) sequencing technologies to decode the genetic material of microorganisms, which allows researchers and healthcare professionals to understand the composition, diversity, and function of these microbial communities.
Increasing incidences of infectious diseases among the masses are catalyzing the demand for microbiome sequencing services for studying host-pathogen relationships, which lead to rising demand for its services around the world. Moreover, the rising inclination towards microbiome-based therapeutics, including fecal microbiota transplantation (FMT), that necessitates accurate microbiome profiling to ensure treatment efficacy and safety is favoring the growth of the market. Apart from this, the growing adoption of microbiome sequencing in veterinary medicine for understanding animal health, disease prevention, and improving livestock production is influencing the market positively. In addition, the expansion of the pharmaceutical industry is driving the use of microbiome data to develop novel drugs, particularly those targeting gastrointestinal diseases, which is contributing to the market growth. Furthermore, the increasing adoption of precision agriculture practices, which rely on data-driven decision-making, is bolstering the market growth.
Increase in personalized medicine and therapies
With the rising use of personalized medicine, there is a rise in the demand for microbiome sequencing services to offer tailoring treatments and interventions to individual patients. One of the driving forces behind the demand for microbiome sequencing services is the recognition that each microbiome of a person is unique and can significantly impact their response to treatments. Whether it is optimizing probiotic regimens, guiding dietary recommendations, or predicting drug efficacy, microbiome data is indispensable. Patients and healthcare providers increasingly seek these insights to achieve better treatment outcomes, minimize adverse effects, and enhance overall wellness. Consequently, the demand for microbiome sequencing services is rising as personalized medicine is becoming a central tenet of modern healthcare.
Rise in consumer awareness and wellness
Consumer awareness about the role of microbiomes in health and wellness has been steadily increasing. People are becoming more proactive about their health, seeking ways to optimize their microbiomes for improved well-being. This trend is driven by the availability of direct-to-consumer microbiome testing kits that provide individuals with insights into their gut microbiota. As consumers gain a better understanding of the connections between their microbiome and various health aspects, they are turning to microbiome sequencing services for in-depth analysis and personalized recommendations. This surge in interest from the public is propelling the demand for microbiome sequencing services, as individuals seek to make informed lifestyle choices and dietary adjustments to promote a healthier microbiome.
Growing regulatory requirements and quality assurance
Regulatory bodies in healthcare, agriculture, and food safety are increasingly recognizing the importance of microbiome data in ensuring safety and quality standards. For instance, in the food industry, microbiome sequencing is used to monitor and improve food safety by identifying potential pathogens or spoilage organisms. Similarly, regulatory agencies in agriculture may require microbiome assessments to ensure sustainable farming practices. Compliance with these regulations necessitates the utilization of microbiome sequencing services to maintain high-quality standards, leading to a consistent demand from businesses and organizations striving to meet regulatory requirements and ensure the safety of their products.
Sequencing by synthesis (SBS) dominates the market
Outsourced research holds the largest share in the market
Wet labs hold the largest share in the market
Shotgun sequencing holds the largest share in the market
Pharmaceutical and biotechnology companies dominate the market
North America exhibits a clear dominance, accounting for the largest microbiome sequencing services market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The increasing knowledge about the advantages of early diagnosis and disease detection represents one of the primary factors driving the demand for microbiome sequencing services in the North American region. Moreover, the surging prevalence of colorectal cancer (CRC) is favoring the growth of the market in the region. Besides this, the growing geriatric population, that are more prone to develop severe medical conditions, is influencing the market positively in the region.
Asia Pacific is estimated to witness stable growth, owing to increasing investment in developing novel drugs, extensive research and development (R&D) activities, integration of advanced technologies, etc.
The leading companies are adopting the use of high throughput sequencing in microbiome sequencing services to enable the simultaneous analysis of numerous microbial samples, which facilitates large-scale studies and delivers high-resolution data on microbial community composition. They are also using metagenomics that allows researchers to sequence the DNA of an entire microbial community in a sample without isolating individual species and enables a holistic view of the microbiome. Moreover, key players are integrating artificial intelligence (AI) and machine learning (ML) into microbiome data analysis that help identify patterns, predict microbial interactions, and discover biomarkers associated with health or disease, which enhances the interpretability of complex microbiome datasets.